STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Krensavage Asset Management Opposes Sun's Lowball Bid for Taro

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

NEW YORK, July 19, 2023 /PRNewswire/ -- As the largest minority shareholder1 of Taro Pharmaceutical Industries Ltd. (NYSE: TARO), Krensavage Asset Management LLC opposes Sun Pharmaceutical Industries Ltd.'s paltry bid to take Taro private.

Sun, a 78.5% Taro shareholder, on May 26 offered to acquire the rest of Taro for $38 a share, valuing the company at $1.4 billion.

Sun's inadequate offer amounts to a 17% discount to the value of Taro's tangible assets2, namely $36 a share of net cash3. If Taro liquidated, shareholders could receive more than $45 a share.

Taro boasts more than just cash and real estate. The maker of generic creams and ointments generated $2.4 billion of cash in the 10 years ended March 31.

Not only is Sun failing to offer a control premium, but it also seemingly ignores Taro's 22 generic drugs awaiting clearance in the U.S., including four with tentative approvals.

With a market value of $31 billion4, Sun can pay more. Sun is offering, net of Taro's cash, $16 million for the roughly 8.1 million Taro shares it doesn't own5.

Taro's actions suggest it agrees with our assessment. In December 2019, Taro paid $91 a share to repurchase its stock in a tender offer – nearly two-and-one-half times Sun's current bid.

Sun's tactics ring familiar. In October 2011, it lowballed Taro's shareholders with a $24.50-a-share bid. Ten months later, Sun raised its offer more than 60% to $39.50 after a special committee of Taro directors rejected the bid.

Sun requires approval of the majority of Taro's minority shareholders. Unless Sun acknowledges Taro's value, we refuse to support the transaction.

 

Notes:

1Krensavage Asset Management's 641,910 shares of Taro on March 31 make it Taro's No. 2 shareholder, according to Bloomberg.

2Tangible assets equal assets of $2.1 billion on March 31 minus goodwill of $17 million and liabilities of $405 million.

3Krensavage defines Taro's net cash as current assets of $1.3 billion plus long-term marketable securities of $405 million minus current liabilities of $386 million.

4Bloomberg lists Sun's closing market cap on July 13 as $31.4 billion.

5Taro had 37,584,631 shares outstanding as of March 31. Sun controlled 29,497,813 shares of Taro according to Sun's May 26 13D/A.

 

Contact:

David W. Walbert

Senior Analyst

Krensavage Asset Management LLC

Office: (212) 706-0589

Info@krensavage.com

Cision View original content:https://www.prnewswire.com/news-releases/krensavage-asset-management-opposes-suns-lowball-bid-for-taro-301880370.html

SOURCE Krensavage Asset Management LLC

Taro Pharmaceutical Inds Ltd

NYSE:TARO

TARO Rankings

TARO Latest News

TARO Stock Data

1.62B
8.09M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
IL
Haifa